ORGANOGENESIS INC. for ORGANOGENESIS INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulation regarding reimbursement for chronic wound healing product
| Lobbyist | Covered position, as disclosed |
|---|---|
| ARTHUR-PAUL PETROSINELLI | — |
Health Issues HCR
Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products S.4348 (FDASLA Act of 2022), regarding FDA policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding FDA policy on chronic wound healing products
| Lobbyist | Covered position, as disclosed |
|---|---|
| ARTHUR-PAUL PETROSINELLI | — |
Defense DEF
Department of Defense research and development funding regarding regenerative medicine products
| Lobbyist | Covered position, as disclosed |
|---|---|
| ARTHUR-PAUL PETROSINELLI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.